Comparative Pharmacology
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus ZIMHI.
NALMEFENE HYDROCHLORIDE vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalmefene is an opioid receptor antagonist with high affinity for mu, kappa, and delta receptors, and partial agonist activity at kappa receptors.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
18 mcg intranasally once, repeated after 2-3 minutes if needed; maximum 2 doses (36 mcg) per episode. Alternatively, 0.5 mg subcutaneously or intramuscularly once, repeated after 2-3 minutes if needed; maximum 1.5 mg per episode.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal elimination half-life: ~10.8 hours (range 8–13 hours); clinically supports twice-daily dosing or use in alcohol use disorder
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Primarily renal (approximately 50% unchanged drug); biliary/fecal excretion accounts for ~20%
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category C
Category C
Opioid Antagonist
Opioid Antagonist